Patents by Inventor Alexander Heim-Riether

Alexander Heim-Riether has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amylin analogues
    Patent number: 11382956
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 12, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
  • AMYLIN ANALOGUES
    Publication number: 20210346468
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: July 21, 2021
    Publication date: November 11, 2021
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • AMYLIN ANALOGUES
    Publication number: 20200188485
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: October 25, 2019
    Publication date: June 18, 2020
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • AMYLIN ANALOGUES
    Publication number: 20190134159
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 9, 2019
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Amylin analogues
    Patent number: 10071140
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 11, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
  • AMYLIN ANALOGUES
    Publication number: 20180071366
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 15, 2018
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
    Patent number: 9139567
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 22, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alexander Heim-Riether, Anil Kumar Padyana, Shuang Liang, Steven John Taylor, Qiang Zhang
  • Alpha-substituted -sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them
    Patent number: 8859814
    Abstract: Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: October 14, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Derek Cogan, Alexander Heim-Riether, Wang Mao, Craig Andrew Miller, Philip Dean Ramsden, Lana Louise Smith Keenan, Roger John Snow, Jiang-Ping Wu, Yu Yang
  • ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
    Publication number: 20140221373
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Application
    Filed: July 17, 2012
    Publication date: August 7, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Alexander Heim-Riether, Anil Kumar Padyana, Shuang Liang, Steven John Taylor, Qiang Zhang
  • Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
    Patent number: 8785489
    Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 22, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Bennett Farmer, Neil Alexander Farrow, Donghong Amy Gao, Alexander Heim-Riether, Lana Louise Smith Keenan, Ingo Andreas Mugge, Steven John Taylor, Zhaoming Xiong, Yang Yu, Qiang Zhang
  • Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S
    Patent number: 8729114
    Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael J. Burke, Derek Cogan, Donghong Amy Gao, Alexander Heim-Riether, Eugene Richard Hickey, Matthew Russell Netherton, Philip Dean Ramsden, David Charles Thompson, Zhaoming Xiong
  • Compounds
    Patent number: 8674113
    Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: March 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Henning Priepke, Henri Doods, Alexander Heim-Riether, Raimund Kuelzer, Roland Pfau, Klaus Rudolf, Dirk Stenkamp
  • Heteroaryl diamide compounds useful as MMP-13 inhibitors
    Patent number: 8637550
    Abstract: Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Neil Alexander Farrow, Donghong Amy Gao, Alexander Heim-Riether, Sabine Schlyer, Lana Louise Smith Keenan, Steven John Taylor, Bernd Wellenzohn, Dieter Wiedenmayer, Zhaoming Xiong, Qiang Zhang
  • 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10
    Patent number: 8586748
    Abstract: This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: November 19, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Derek Cogan, Younggi Choi, Donghong A. Gao, Daniel R. Goldberg, Alexander Heim-Riether, Craig Andrew Miller, Philip Dean Ramsden, Lana Louise Smith Keenan, Roger John Snow, Yang Yu
  • Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
    Patent number: 8552205
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Antonio Jose del Moral Barbosa, Jr., Joerg Martin Bentzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan McKibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S
    Publication number: 20130158018
    Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.
    Type: Application
    Filed: March 2, 2011
    Publication date: June 20, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael J. Burke, Derek Cogan, Donghong Amy Gao, Alexander Heim-Riether, Eugene Richard Hickey, Matthew Russell Netherton, Philip Dean Ramsden, David Charles Thompson, Zhaoming Xiong
  • Fused heteroaryl diamide compounds useful as MMP-13 inhibitors
    Patent number: 8338367
    Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alexander Heim-Riether, Shuang Liang, Sabine Schlyer
  • CCR10 antagonists
    Patent number: 8299123
    Abstract: The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: October 30, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kaka Dey, Donghong Amy Gao, Daniel R. Goldberg, Alexander Heim-Riether, John Edward Mangette, Ingo Andreas Mugge, Roger John Snow, Alan David Swinamer, Jiang-Ping Wu, Zhaoming Xiong, Yu Yang
  • NOVEL COMPOUNDS
    Publication number: 20120149676
    Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.
    Type: Application
    Filed: December 8, 2011
    Publication date: June 14, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Henning PRIEPKE, Henri DOODS, Alexander HEIM-RIETHER, Raimund KUELZER, Roland PFAU, Klaus RUDOLF, Dirk STENKAMP
  • 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
    Patent number: 8093245
    Abstract: 4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: January 10, 2012
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: David J. Augeri, Marianne Carlsen, Kenneth G. Carson, Qinghong Fu, Alexander Heim-Riether, Theodore C. Jessop, James E. Tarver, Jerry A. Taylor